US8268848 — Cyclopropane compound
Method of Use · Assigned to Eisai R&D Management Co Ltd · Expires 2031-09-20 · 5y remaining
What this patent protects
A cyclopropane compound represented by the following formula (A) or a pharmaceutically acceptable salt thereof has orexin receptor antagonism, and therefore has a potential use for the treatment of sleep disorder for which orexin receptor antagonism is effective, for example, ins…
USPTO Abstract
A cyclopropane compound represented by the following formula (A) or a pharmaceutically acceptable salt thereof has orexin receptor antagonism, and therefore has a potential use for the treatment of sleep disorder for which orexin receptor antagonism is effective, for example, insomnia: wherein Q represents âCHâ or a nitrogen atom, R1a and R1b each independently represent a C1-6 alkyl group and the like, R1c represents a hydrogen atom and the like, R2a, R2b, R2c and R2d each independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group and the like, R3a, R3b and R3c each independently represent a hydrogen atom, a halogen atom and the like, and R3d represents a hydrogen atom and the like.
Drugs covered by this patent
- Dayvigo (LEMBOREXANT) · Eisai
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2791 |
— | Dayvigo |
U-2791 |
— | Dayvigo |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.